Zava Secures $32 Million Series A Funding to Expand Telehealth Platform Across Europe

VCBeat (WeChat ID: vcbeat) learned from foreign media that on June 12 local time, the medical technology company Zava completed a $32 million Series A financing round. The round was led by HPE Growth. Zava will use the funds to expand its team, promote its healthcare platform across Europe, and plans to launch statutory healthcare systems in Germany, the United Kingdom, and France.

Zava is a digital health company founded in 2010 and headquartered in London, United Kingdom. The company has established an official website that provides services such as medical consultations, online diagnoses, and medication delivery, enabling patients to access remote healthcare services via the internet. In 2012, Zava completed a $1.4 million angel funding round.

Through Zava’s platform, patients can easily communicate with doctors online and access medical services more conveniently. First, patients are required to complete an online medical questionnaire on the website, providing detailed information about their symptoms, medical history, and personal circumstances. This questionnaire was developed by Zava’s clinical team and has undergone rigorous testing. Subsequently, Zava assigns a physician to review this medical information. Based on the patient’s condition, the physician will determine the next steps, such as issuing a prescription, ordering diagnostic tests, providing health advice, or requesting additional information, ultimately formulating the optimal treatment plan. Once the treatment plan is established, Zava delivers the necessary medications or test kits to the patient. After the consultation is completed, patients can rate and review the service on the website.

Currently, Zava’s services are available in the United Kingdom, Germany, France, Austria, Switzerland, and Ireland. Since its inception, Zava has provided three million paid consultations to users across these six countries. The company states that nearly 100,000 patients use its services each month, seeking advice, testing, or treatment for a variety of medical conditions.

Zava’s early profits stemmed from paid services provided to patients, as well as partnerships with insurance companies and pharmacies. In the next phase, Zava plans to introduce a dual-track model in key markets such as the United Kingdom—offering direct-to-consumer paid consultations while also collaborating with the state-funded National Health Service (NHS) to provide free telemedicine services to patients. Going forward, Zava will focus on women’s health and mental health, and will launch new testing kits.

David Meinertz, co-founder and CEO of Zava, stated, “The medical questionnaires we provide are identical to the questions asked by general practitioners during consultations. The difference is that patients can complete the questionnaires in a more relaxed setting, avoiding the awkwardness of discussing private medical information face-to-face with a doctor. In this environment, patients’ responses tend to be more comprehensive and candid, which better facilitates clinical judgment. The medical services provided by Zava enable doctors to treat patients more effectively and safely.”

Harry Dolman, a partner at HPE Growth, commented, “Zava offers a unique, highly scalable model that provides patients with more convenient access to healthcare services while fundamentally improving the efficiency of medical professionals. This model has the potential to reduce the overall costs associated with primary care within the healthcare system.”

HPE Growth is a European private equity firm established in 2010, headquartered in Amsterdam, the Netherlands. The firm focuses on growth capital investments in technology companies across Northern and Western Europe, managing assets exceeding €500 million. HPE Growth primarily invests in companies with mature technologies or those holding leading positions in their local markets, facilitating their expansion by providing additional equity and funding. Typically, HPE Growth invests between €10 million and €40 million per transaction.

(Compiled by Wang Yi)